Nagar Saumya, Trudler Dorit, McKercher Scott R, Piña-Crespo Juan, Nakanishi Nobuki, Okamoto Shu-Ichi, Lipton Stuart A
Neuroscience and Aging Research Center and Graduate School of Biomedical Sciences, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States.
Neurodegenerative Disease Center, Scintillon Institute, San Diego, California, United States.
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3741-3749. doi: 10.1167/iovs.17-21767.
Photoreceptor degeneration in the retina is a major cause of blindness in humans. Elucidating mechanisms of degenerative and neuroprotective pathways in photoreceptors should afford identification and development of therapeutic strategies.
We used mouse genetic models and improved methods for retinal explant cultures. Retinas were enucleated from Mef2d+/+ and Mef2d-/- mice, stained for MEF2 proteins and outer nuclear layer thickness, and assayed for apoptotic cells. Chromatin immunoprecipitation (ChIP) assays revealed MEF2 binding, and RT-qPCR showed levels of transcription factors. We used AAV2 and electroporation to express genes in retinal explants and electroretinograms to assess photoreceptor functionality.
We identify a prosurvival MEF2D-PGC1α pathway that plays a neuroprotective role in photoreceptors. We demonstrate that Mef2d-/- mouse retinas manifest decreased expression of PGC1α and increased photoreceptor cell loss, resulting in the absence of light responses. Molecular repletion of PGC1α protects Mef2d-/- photoreceptors and preserves light responsivity.
These results suggest that the MEF2-PGC1α cascade may represent a new therapeutic target for drugs designed to protect photoreceptors from developmental- and age-dependent loss.
视网膜中的光感受器退化是人类失明的主要原因。阐明光感受器中退化和神经保护途径的机制应有助于治疗策略的识别和开发。
我们使用小鼠遗传模型和改进的视网膜外植体培养方法。从Mef2d+/+和Mef2d-/-小鼠中摘除视网膜,对MEF2蛋白和外核层厚度进行染色,并检测凋亡细胞。染色质免疫沉淀(ChIP)分析揭示了MEF2的结合,RT-qPCR显示了转录因子的水平。我们使用AAV2和电穿孔在视网膜外植体中表达基因,并用电视网膜图评估光感受器的功能。
我们鉴定出一条促生存的MEF2D-PGC1α途径,该途径在光感受器中起神经保护作用。我们证明Mef2d-/-小鼠视网膜中PGC1α的表达降低,光感受器细胞损失增加,导致无光反应。PGC1α的分子补充可保护Mef2d-/-光感受器并保留光反应性。
这些结果表明,MEF2-PGC1α级联可能代表一种新的治疗靶点,用于设计旨在保护光感受器免受发育和年龄依赖性损失的药物。